Navigation Links
Public attitudes to new technology: Lessons for regulators

(Santa Barbara, California) New technologies may change our lives for the better, but sometimes they have risks. Communicating those benefits and risks to the public, and developing regulations to deal with them, can be difficult particularly if there's already public opposition to the technology.

A new study that provides an overview of research on public perceptions of nanotechnology technology on a very, very small scale challenges some current ideas of how people view the risks and benefits of new technology. The work has implications for how policymakers talk about and regulate new technologies.

Public views on nanotechnology, which could revolutionize medicine, electronics and energy technology, but has possible health and environmental risks, are overwhelmingly favorable, the study found. However many people hadn't heard of nanotechnology, and nearly half those surveyed in North America, Europe and Japan weren't sure what they thought of it. It's reassuring that those people haven't made hasty judgments, the authors say, but that means that bungled attempts to educate the public about nanotechnology, or to regulate it, could turn public opinion against this promising technology.

"If you only talk about benefits it doesn't mean the public will buy the product and everyone lives happily ever after. We know that is not a good scenario," says Barbara Herr Harthorn, Director and Principal Investigator of the National Science Foundation-funding Center for Nanotechnology in Society at the University of California, Santa Barbara (CNS-UCSB).

Harthorn is one of the authors of a study "Anticipating the perceived risk of nanotechnologies" appearing online Sept. 20 in the journal Nature Nanotechnology. It is based on data from 22 surveys conducted over the last decade.

Previous studies have found that new and unknown technologies such as biotechnology tend to be regarded as risky, but that's not the case for nanotechnology, according to this research. People who thought nanotechnology had more benefits than risks outnumbered those who perceived greater risks by 3 to 1 in this study. The 44 percent of people who didn't have an opinion either way surprised the researchers.

"You don't normally get that reluctance," says Terre Satterfield of the University of British Columbia in Canada, lead author of the study and a collaborator with CNS-UCSB.

It's important to study how people perceive risk, and not just expert assessments of actual risk, Herr Harthorn says, because it's "a much better way to understand how people are going to behave and respond."

"It's not true that if a technology has benefits it will automatically get accepted by the public," adds Milind Kandlikar of the University of British Columbia. He is also a collaborator with CNS-UCSB and a co-author of the study, along with Joseph Conti, a former graduate fellow with CNS-UCSB, and Christian Beaudrie of the University of British Columbia.

Public perceptions of risk depend on various demographic and cultural factors; for example, wealthy, well-educated white men tend to think of new technologies as less risky. Public opinion also is easily swayed by catastrophic events like the Chernobyl accident, which galvanized opposition to nuclear power, and by news like reports of deaths from Bovine spongiform encephalopathy (BSE) in Europe, or from severe acute respiratory syndrome (SARS) or swine flu (the H1N1 virus).

"It's much easier to destroy trust than gain it," Satterfield says, so after an event like a nuclear meltdown or oil spill, leaders need to "take responsibility for any consequences quickly and clearly."

Because nanotechnology hasn't made big news, it offers researchers a chance to study how people judge new technology before controversy arises. "The future is yet to be written. Judgments could go either way," Satterfield says.


Contact: Barbara Herr Harthorn
University of California - Santa Barbara

Related biology technology :

1. Omeros Commences Initial Public Offering of Common Stock
2. Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock
3. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Feasible in Patients Requiring Undeferrable Non-Cardiac Surgery, International Journal of Cardiology Publication Reports
4. Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network (PHIN) Conference
5. Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company
6. Accera Announces Peer-Reviewed Publication of the Results of its 90-Day Clinical Study of AC-1202 (Axona(TM) ) in Mild to Moderate Alzheimers Disease
7. Cumberland Pharmaceuticals Announces Pricing of Its Initial Public Offering of Common Stock
8. Micromet Closes $80.5 Million Public Offering of Common Stock
9. Human Genome Sciences Announces Closing of Public Offering
10. Micromet Announces Pricing of Public Offering of Common Stock
11. Micromet Announces Public Offering of Common Stock
Post Your Comments:
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology:
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):